Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10608
Title: The insulin-like growth factor system: towards clinical applications.
Authors: Bach, Leon A
Affiliation: University of Melbourne, Department of Medicine (Austin Health/Northern Health) Austin Hospital, Heidelberg, VIC, Australia. l.bach@unimelb.edu.au
Issue Date: 1-Aug-2004
Citation: The Clinical Biochemist. Reviews / Australian Association of Clinical Biochemists; 25(3): 155-64
Abstract: Insulin-like growth factors (IGF-I and II) are important endocrine, paracrine and autocrine mediators of physiological growth. They promote cellular proliferation, survival and differentiation. Their effects are mediated mainly through the IGF-I receptor, but IGFs also bind to the IGF-II/mannose 6-phosphate and insulin receptors. IGF activity is modulated by a family of six high-affinity IGF binding proteins (IGFBPs); in most situations, IGFBPs inhibit IGF actions but they may also enhance them. Assays are now available for IGF-I, IGF-II and individual IGFBPs. IGF-I and IGFBP-3 assays have some utility in the diagnosis and management of acromegaly and growth hormone deficiency. There is a large body of in vitro and in vivo evidence supporting a pathogenic role for alterations in the IGF system in many diseases, including diabetes, cancer, cardiovascular disease and neuromuscular disease. More recently, epidemiological studies have linked high IGF-I levels with some cancers and low IGF-I levels with ischaemic heart disease. Preliminary studies of recombinant IGF-I as a treatment for diabetes, osteoporosis and neuromuscular disease have been performed in humans. In contrast, there is considerable interest in developing IGF inhibitors for the treatment of cancer. This apparent paradox highlights the need to develop therapeutics beyond the natural ligands and inhibitors, with characteristics such as ligand and tissue specificity. This will only become possible as we increase our understanding of this complex system. Additionally, as IGF and IGFBP assays are becoming more readily available, their role in the diagnosis and monitoring of diseases should be more clearly defined in the near future.
Internal ID Number: 18458708
URI: http://ahro.austin.org.au/austinjspui/handle/1/10608
URL: http://www.ncbi.nlm.nih.gov/pubmed/18458708
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.